SOPHiA GENETICS Raises 2025 Revenue Guidance After 23% Q3 Growth

SOPHiA GENETICS reported third-quarter 2025 financial results, announced in a press release. Revenue reached $19.5 million, up 23% year-over-year. The company’s gross margin was 66.3% on a reported basis and 73.1% on an adjusted basis. Net IFRS loss totaled $20 million, while adjusted EBITDA loss was $10.2 million, or $8.8 million excluding the impact of elevated Swiss social charges on equity-based compensation.

SOPHiA GENETICS raised its full-year 2025 revenue outlook to a range of $75 million to $77 million, compared to the previous $72 million to $76 million estimate. Adjusted EBITDA loss is expected to be between $39 million and $41 million. The company reiterated its goal of reaching adjusted EBITDA breakeven by the end of 2026 and positive adjusted EBITDA in the second half of 2027.

During the quarter, SOPHiA GENETICS signed 31 new customers for its SOPHiA DDM platform, an increase from 22 in the same period last year, with average contract value up 180% year-over-year. The company performed a record 99,000 analyses on the platform and expanded its customer base to 488 core genomics clients. U.S. revenue grew 30% year-over-year, driven by new customers including Baylor Scott & White Health and Geisinger Health System.

The company also reported continued adoption of its Liquid Biopsy application, MSK-ACCESS powered with SOPHiA DDM, and launched SOPHiA DDM Digital Twins, an AI-powered research technology for oncology. New partnerships were signed with Myriad Genetics, A.D.A.M. Innovations, and AstraZeneca to develop and validate new genomic and AI-driven diagnostic solutions.